Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

被引：1

作者：

Elder, Mary J. ^{[1
]}

Ashjian, Emily J. ^{[2
]}

机构：

[1] Michigan Med, Pharm Innovat & Partnerships, 2500 Green Rd,Suite 100, Ann Arbor, MI 48105 USA

[2] Univ Michigan, Coll Pharm, Dept Clin Pharm, Ann Arbor, MI 48109 USA

来源：

JOURNAL OF PHARMACY PRACTICE | 2023年 / 36卷 / 02期

关键词：

diabetes mellitus; glucagon-like peptide-1 receptor agonist; gastric inhibitory polypeptide; G protein-coupled receptor 119 agonist; glucagon receptor agonist; RECEPTOR AGONIST; CHINESE PATIENTS; DOUBLE-BLIND; PHARMACODYNAMICS; PHARMACOKINETICS; SAFETY; METFORMIN; RG7697; SINGLE;

D O I：

10.1177/08971900211049032

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying. These properties make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are many FDA-approved GLP-1 agonists on the market today, several of which have demonstrated benefit beyond improving glycemic control. Given the beneficial effects of GLP-1 agonists in patients with T2DM, new drugs are in development that combine the mechanism of action of GLP-1 receptor agonism with novel mechanisms and with drugs that promote GLP-1 secretion. These agents are designed to improve glycemic control and target greater body weight reduction. This article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.

引用

页码：418 / 428

页数：11

共 50 条

[41] STRUCTURE OF HUMAN GLP-1 (GLUCAGON-LIKE PEPTIDE-1) CONTAINING PEPTIDES
ORSKOV, C
KOFOD, H
RABENHOJ, L
WETTERGREN, A
HOLST, JJ
REGULATORY PEPTIDES, 1992, 40 (02) : 223 - 223
[42] Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Ja'arah, Daria
Al Zoubi, Mazhar Salim
Abdelhady, Gamal
Rabi, Firas
Tambuwala, Murtaza M.
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2021, 14
[43] Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
Ang, Richard
Mastitskaya, Svetlana
Hosford, Patrick S.
Basalay, Marina
Specterman, Mark
Aziz, Qadeer
Li, Yiwen
Orini, Michele
Taggart, Peter
Lambiase, Pier D.
Gourine, Andrey
Tinker, Andrew
Gourine, Alexander V.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2018, 11 (10): : e006740
[44] Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Wroge, Jamie
Williams, Nancy Toedter
ANNALS OF PHARMACOTHERAPY, 2016, 50 (12) : 1041 - 1050
[45] STRUCTURE OF HUMAN GLP-1(GLUCAGON-LIKE PEPTIDE-1) CONTAINING PEPTIDES
ORSKOV, C
KOFOD, H
RABENHOJ, L
WETTERGREN, A
HOLST, JJ
DIABETOLOGIA, 1992, 35 : A109 - A109
[46] Efpeglenatide Glucagon-like peptide 1 (GLP-1) receptor agonist Treatment for type 2 diabetes
Reid, J.
Rana, K.
Segel, S. A.
Sheikh-Ali, M.
Choksi, R. R.
Goldfaden, R. F.
DRUGS OF THE FUTURE, 2019, 44 (06) : 435 - 441
[47] Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes
Nauck, MA
Holst, JJ
Willms, B
Schmiegel, W
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1997, 105 (04) : 187 - 195
[48] Improving Glucagon-like Peptide-1 Dynamics in Patients With Type 2 Diabetes Mellitus
Freeman, Jeffrey S.
JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2012, 112 (01): : S2 - S6
[49] Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1
Holst, JJ
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 (06) : 430 - 441
[50] Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?
Garcia-Casares, Natalia
Antonio Garcia-Arnes, Juan
Gomez-Huelgas, Ricardo
Valdivielso-Felices, Pedro
Garcia-Arias, Carlota
Gonzalez-Santos, Pedro
REVISTA DE NEUROLOGIA, 2014, 59 (11) : 517 - 524

← 1 2 3 4 5 →